FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3089309872> ?p ?o ?g. }

• W3089309872 endingPage "S273" @default.
• W3089309872 startingPage "S273" @default.
• W3089309872 abstract "Immunotherapy is a new treatment which has shown initial efficacy for cholangiocarcinoma patients (pts). Biliary radioactivity particle stent placement can effectively solve the obstruction of pts with advanced perihilar cholangiocarcinoma (PCC) and affect immune function, although the mechanism by which this occurs is not clear. Hepatic Arterial Infusion (HAI) treatment of advanced PCC can inhibit tumour growth, however, the impact on immune function needs to be explored. Therefore, the immune function and prognosis of advanced PCC pts who are receiving different therapies is worth further exploration. This study is a prospective, open-label, multi-cohort clinical study. Pts with advanced PCC (75 pts) are allocated to three cohorts (1:1:1) according to informed and voluntary consent. Cohort A: 125I particle stent + HAI + camrelizumab; Cohort B: 125I particle stent + camrelizumab; Cohort C: HAI + camrelizumab. Methods of particle implantation are dependent on patients' condition of disease (the size of the tumor/TPS plan before particle implantation etc.). HAI plan: HAI consisted of infusions of oxaliplatin 40 mg/ m2 for 2 hours, followed by 5-fluorouracil 800 mg/m2 for 22 hours on days 1∼3 every 3 weeks, a maximum of 6 cycles of HAI are applied for tumor control patients followed by maintenance with oral capecitabine until tumor progression. Camrelizumab (200mg) is administered every 3 weeks up to 12 months. Efficacy and safety are evaluated after 1 cycle first and every 3 cycles follow-up. Primary endpoints are objective response rate (ORR) and safety. Secondary endpoints includes progress free survival (PFS), near-term outcome indicators (TBIL/DBIL/AST/ALT/ CEA/CA199 etc.), long-term outcome indicators (stent patency rate/ tumour response rate etc.), complications (fever/ bleeding/pain etc.), changes in immune-inflammatory cytokines (TNF-α/IL-1β/IL-6/ IL-8/CD4/CD8/IgA/IgG/IgM/complement C3 and C4), etc. The authors." @default.
• W3089309872 created "2020-10-01" @default.
• W3089309872 creator A5019253468 @default.
• W3089309872 creator A5074438121 @default.
• W3089309872 creator A5078924153 @default.
• W3089309872 creator A5083705008 @default.
• W3089309872 creator A5086804517 @default.
• W3089309872 date "2020-09-01" @default.
• W3089309872 modified "2023-10-16" @default.
• W3089309872 title "81TiP Changes in immune function and prognosis in advanced perihilar cholangiocarcinoma patients treated with immunotherapy combined with different topical therapies" @default.
• W3089309872 doi "https://doi.org/10.1016/j.annonc.2020.08.152" @default.
• W3089309872 hasPublicationYear "2020" @default.
• W3089309872 type Work @default.
• W3089309872 sameAs 3089309872 @default.
• W3089309872 citedByCount "0" @default.
• W3089309872 crossrefType "journal-article" @default.
• W3089309872 hasAuthorship W3089309872A5019253468 @default.
• W3089309872 hasAuthorship W3089309872A5074438121 @default.
• W3089309872 hasAuthorship W3089309872A5078924153 @default.
• W3089309872 hasAuthorship W3089309872A5083705008 @default.
• W3089309872 hasAuthorship W3089309872A5086804517 @default.
• W3089309872 hasBestOaLocation W30893098721 @default.
• W3089309872 hasConcept C121608353 @default.
• W3089309872 hasConcept C126322002 @default.
• W3089309872 hasConcept C141071460 @default.
• W3089309872 hasConcept C143998085 @default.
• W3089309872 hasConcept C168563851 @default.
• W3089309872 hasConcept C203092338 @default.
• W3089309872 hasConcept C2777701055 @default.
• W3089309872 hasConcept C71924100 @default.
• W3089309872 hasConcept C72563966 @default.
• W3089309872 hasConcept C90924648 @default.
• W3089309872 hasConceptScore W3089309872C121608353 @default.
• W3089309872 hasConceptScore W3089309872C126322002 @default.
• W3089309872 hasConceptScore W3089309872C141071460 @default.
• W3089309872 hasConceptScore W3089309872C143998085 @default.
• W3089309872 hasConceptScore W3089309872C168563851 @default.
• W3089309872 hasConceptScore W3089309872C203092338 @default.
• W3089309872 hasConceptScore W3089309872C2777701055 @default.
• W3089309872 hasConceptScore W3089309872C71924100 @default.
• W3089309872 hasConceptScore W3089309872C72563966 @default.
• W3089309872 hasConceptScore W3089309872C90924648 @default.
• W3089309872 hasLocation W30893098721 @default.
• W3089309872 hasOpenAccess W3089309872 @default.
• W3089309872 hasPrimaryLocation W30893098721 @default.
• W3089309872 hasRelatedWork W2002120878 @default.
• W3089309872 hasRelatedWork W2003938723 @default.
• W3089309872 hasRelatedWork W2047967234 @default.
• W3089309872 hasRelatedWork W2118496982 @default.
• W3089309872 hasRelatedWork W2439875401 @default.
• W3089309872 hasRelatedWork W2981585339 @default.
• W3089309872 hasRelatedWork W3213078359 @default.
• W3089309872 hasRelatedWork W4289517314 @default.
• W3089309872 hasRelatedWork W4306253774 @default.
• W3089309872 hasRelatedWork W2525756941 @default.
• W3089309872 hasVolume "31" @default.
• W3089309872 isParatext "false" @default.
• W3089309872 isRetracted "false" @default.
• W3089309872 magId "3089309872" @default.
• W3089309872 workType "article" @default.